Experimental HIV Vaccine Demonstrates Strong Protection in Preclinical Primate Research

What if scientists are finally teaching the immune system to outsmart HIV? A new experimental HIV vaccine has shown promising results in preclinical studies by triggering rare, broadly neutralising antibodies (bnAbs) capable of targeting the virus despite its rapid mutations.

Developed by researchers from the La Jolla Institute for Immunology (LJI), Scripps Research, and the International AIDS Vaccine Initiative (IAVI), the vaccine is the first to generate high levels of these powerful antibodies in primates. The findings were published in the journal Nature.

Unlike traditional vaccines, this candidate focuses on guiding B cells—the immune cells that produce antibodies—through a carefully designed maturation process. HIV has long evaded vaccines because it constantly mutates, disguises itself with sugar molecules called glycans, and changes its shape during infection, making it difficult for antibodies to recognise and neutralise the virus.

To overcome these challenges, researchers traced the development of rare broadly neutralising antibodies found in a small number of people living with HIV. By studying how these antibodies evolved, they designed vaccine molecules that mimic key regions of HIV's outer envelope protein, training immature B cells to develop into antibody-producing cells capable of recognising vulnerable viral targets.

The vaccine was tested in rhesus macaques at the Emory National Primate Research Center. Around 44% of the animals developed broadly neutralising antibodies against HIV, with antibody levels considered strong enough to support further research.

Researchers say the findings mark a significant advance toward a preventive HIV vaccine, though human clinical trials are still required to confirm safety and effectiveness. If successful, this strategy could transform HIV prevention by enabling the immune system to generate the rare antibodies needed to combat one of the world's most challenging viruses.

REFERENCE: Steichen, J. M., et al. (2026) Vaccination elicits HIV broadly neutralizing antibodies in primates. Nature. DOI: 10.1038/s41586-026-10837-5. https://www.nature.com/articles/s41586-026-10837-5-